ConforMIS Inc (NASDAQ:CFMS) saw a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 1,750,599 shares, a drop of 30.3% from the January 12th total of 2,511,764 shares. Based on an average daily volume of 1,295,167 shares, the days-to-cover ratio is currently 1.4 days. Currently, 5.2% of the company’s shares are short sold.

ConforMIS (CFMS) traded down $0.05 during trading on Wednesday, reaching $1.41. The company’s stock had a trading volume of 379,004 shares, compared to its average volume of 873,942. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.38 and a current ratio of 6.19. The company has a market cap of $87.70, a PE ratio of -1.14 and a beta of 1.41. ConforMIS has a fifty-two week low of $1.15 and a fifty-two week high of $8.61.

ConforMIS (NASDAQ:CFMS) last posted its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.03. The business had revenue of $20.80 million for the quarter, compared to analysts’ expectations of $20.07 million. ConforMIS had a negative return on equity of 78.44% and a negative net margin of 68.59%. The business’s revenue was down 4.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.37) EPS. equities analysts forecast that ConforMIS will post -0.86 EPS for the current year.

Several analysts recently issued reports on the company. Zacks Investment Research cut ConforMIS from a “hold” rating to a “sell” rating in a research note on Wednesday, January 24th. Canaccord Genuity cut their target price on ConforMIS from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Thursday, February 8th. BTIG Research reissued a “hold” rating on shares of ConforMIS in a research note on Thursday, November 2nd. JPMorgan Chase & Co. cut ConforMIS from a “neutral” rating to an “underweight” rating in a research note on Tuesday, January 2nd. Finally, Oppenheimer set a $4.00 target price on ConforMIS and gave the stock a “buy” rating in a research note on Thursday, February 8th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $4.88.

In related news, CEO Mark A. Augusti sold 16,548 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $2.27, for a total value of $37,563.96. Following the sale, the chief executive officer now directly owns 285,007 shares of the company’s stock, valued at $646,965.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 43,691 shares of company stock worth $91,154 over the last three months. 9.55% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the business. Stonebridge Capital Management Inc. bought a new stake in shares of ConforMIS in the 3rd quarter worth approximately $130,000. The Manufacturers Life Insurance Company boosted its position in shares of ConforMIS by 21.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,121 shares of the medical instruments supplier’s stock worth $158,000 after purchasing an additional 6,535 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of ConforMIS by 31.1% in the 2nd quarter. Alliancebernstein L.P. now owns 40,000 shares of the medical instruments supplier’s stock worth $172,000 after purchasing an additional 9,500 shares in the last quarter. Rhumbline Advisers boosted its position in shares of ConforMIS by 21.8% in the 2nd quarter. Rhumbline Advisers now owns 44,782 shares of the medical instruments supplier’s stock worth $192,000 after purchasing an additional 8,017 shares in the last quarter. Finally, Swiss National Bank boosted its position in shares of ConforMIS by 59.2% in the 2nd quarter. Swiss National Bank now owns 53,500 shares of the medical instruments supplier’s stock worth $230,000 after purchasing an additional 19,900 shares in the last quarter. 26.99% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This piece of content was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/02/14/conformis-inc-cfms-short-interest-down-30-3-in-january.html.

ConforMIS Company Profile

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.